# Harrow, Inc. (HROW) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/HROW
## Company Profile
- Ticker: HROW
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Ophthalmology
## Stock Data
- Close: 39.36 USD
- Market cap: 1224860016.02 USD
- Last updated: 2026-08-12
## Business Overview
### Ophthalmic Pharmaceutical Portfolio
Harrow is a U.S. ophthalmic pharmaceutical company commercializing branded and compounded medicines for eye-care professionals. Its portfolio addresses conditions managed in optometry, ophthalmology and surgical settings.
### Dry-Eye Franchise
VEVYE is a cyclosporine ophthalmic solution for the signs and symptoms of dry-eye disease. It is positioned as a differentiated prescription option within a large chronic-treatment market.
### Surgical and Retina Products
IHEEZO is a single-use ocular anesthetic gel used for ophthalmic procedures. Harrow also markets additional products serving retina practices and other segments of eye care through a specialized commercial organization.
## Why The Stock Is Moving

As of Aug 12, 2026, HROW was little changed and closed at $39.36. No new same-company headline was identified in the current news window.

## Future Catalysts

- Harrow's catalysts are VEVYE and IHEEZO commercialization, plus continued ophthalmology portfolio expansion. The company is still building out a broader eye-care base that can support more durable growth.

## Recent News
- 2026-08-10 20:05 EST — [Harrow Announces Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/HROW/harrow-announces-second-quarter-2026-financial-results-c1a885b4) — Source: Harrow, Inc.
- 2026-08-06 11:00 EST — [Harrow Acquires Global Rights to TYRVAYA®,  the First and Only FDA-Approved Nasal Spray for Dry Eye Disease](https://biopharmsignal.com/news/HROW/harrow-acquires-global-rights-to-tyrvaya-the-first-and-only-fda-approved-nasal-s-6685d2e8) — Source: Harrow, Inc.
- 2026-07-27 11:00 EST — [Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026](https://biopharmsignal.com/news/HROW/harrow-to-report-second-quarter-2026-financial-results-after-market-close-on-aug-38f34b84) — Source: Harrow, Inc.
- 2026-07-20 12:00 EST — [Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026](https://biopharmsignal.com/news/HROW/samsung-bioepis-and-harrow-present-interim-data-from-a-large-scale-post-marketin-f2b635bb) — Source: Harrow, Inc.
- 2026-07-20 11:00 EST — [Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting](https://biopharmsignal.com/news/HROW/harrow-highlights-growing-clinical-evidence-supporting-iheezo-and-byooviz-at-asr-8b380ee4) — Source: Harrow, Inc.